The 2020 Adolescent and Adult Asthma Guidelines recommend fundamental changes in asthma management based on recent advances in knowledge.
The major changes are:
• the recommendation to avoid SABA-only treatment in the long-term management of asthma.
• the use of budesonide/formoterol reliever, with or without maintenance budesonide/formoterol, is preferred to short-acting beta2-agonist (SABA) reliever, with or without maintenance ICS or ICS/LABA, across the spectrum of asthma severity.
These recommendations are based on clinical trials which showed that a budesonide/formoterol inhaler, taken as needed, reduces the risk of a severe asthma attack by between 30% and 60% compared to SABA reliever therapy.
Childhood asthma is a significant condition, disproportionately affecting
Māori and Pasifika. Although the drug treatment of asthma is well known,
adherence is low and outcomes are poor. This session describes the
diagnostic process for childhood asthma and treatment. Emphasis is given to improving health literacy and adherence.
This year has seen the development of our first NZ COPD Guidelines. This guideline is designed as a quick reference to provide simple, practical, evidence-based recommendations for the diagnostic, assessment and management of Chronic Obstructive Pulmonary Disease (COPD) in clinical practice. During this session we will walk our way through the key aspects of the guidelines.
This session will focus on the Asthma and COPD fundamentals e-learning series developed by the Asthma and Respiratory Foundation NZ.
The COVID-19 pandemic has brought about unprecedented challenges as well as opportunities to explore new ways of delivering healthcare. There has never been a better time than now to explore the potential of digital technology as an alternative channel of supporting asthma care. This session discusses the different digital technologies that exist for asthma
management and invites the audience to consider the potential of these technologies in changing practice and healthcare delivery.
The session will cover the evidence on digital interventions, the impact of online media in influencing asthma care, and the implications of these for current and future practice.
An overview of the burden of RSV disease in New Zealand, the progress towards an available effective vaccine for mothers and infants with detailed reference to the Novamax M301 trial and the impact of COVID-19 public health interventions on the burden of RSV in New Zealand and overseas.
PHARMAC is the Government Agency responsible for securing for the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.
Logan will provide an update on some of the recent work on respiratory health that PHARMAC has been undertaking, including the process PHARMAC takes in funding medicines
some of the recent funding and procurement processes that have been undertaken, and providing some information on our Medicines Access Equity programme of work, where respiratory health is one of the priority areas. There will also be the opportunity to ask questions about the work that PHARMAC undertakes.
Māori are calling for the Crown to recognise their tino rangatiratanga and mana motuhake through a stand-alone independent Māori Health Authority. In 2005 the Wai 1315 Primary Health claim was submitted to the Waitangi
Tribunal. Fifteen years later in 2019 it was heard as part of the Wai 2575 Hauora claim. The Tribunal recommended that the Crown work with the Claimants to develop a draft terms of reference for a Māori Health Authority. The Heather Simpson, New Zealand Health and Disability System Review final report, also recommended a Māori health authority. Can it be that Māori and the Crown are finally on the same page?
Respiratory disease costs the country more than seven billion dollars a
year, with costs expected to rise in the coming years. Health inequity is
prevalent among Māori and Pacific peoples resulting in increased rates of
hospitalisation and mortality. Sixty individuals with respiratory disease,
along with their whānau (175 in total)
were invited to take part in the Whaimua Programme. The programme’s goal is to support whānau to better self-manage their condition by working on the things that matter most to them. A new model of care was developed using a Whanau Ora approach with the Te Whare Tapa Whā model underpinning the programme. Whakawhanaungatanga has played a key role in its success. The results have been overwhelmingly positive as captured in both subjective and objective data. This model of care challenges the conventional approach to health management for those with long term conditions.
Keri Brown is a proud Wainuiomata resident with two children. She comes from a community and public service background, working in public policy, employment and non government organisational funding. She has been an adviser to a Minister of Māori Affairs and is particularly interested in outcomes framework design.
Working in the Wainuiomata and Lower Hutt community for the last eight years has provided in-depth understanding of the developing housing and homeless issues. She is a strong advocate for housing and homelessness and played a key role in Hutt City Council adopting a three-year homeless strategy and is a board member of Urban Plus, a Council Controlled Organisation that focuses on housing.